Anti-Mouse CD127 (IL-7Rα) [Clone A7R34] — Purified in vivo GOLD™ Functional Grade

Clone A7R34 is an anti-mouse CD127 (IL-7Rα) monoclonal antibody that is widely used in in vivo mouse studies to explore the biological roles of CD127, a component critical for lymphocyte development and homeostasis. Its primary applications in in vivo studies include:

• Blocking IL-7 signaling: A7R34 blocks IL-7 binding to CD127, thereby inhibiting IL-7-mediated signaling pathways in mice. This allows researchers to assess the role of IL-7/IL-7R interactions in immune system development, T and B cell biology, and immune homeostasis.
• Functional studies: By administering A7R34 in vivo, researchers can deplete or modulate the activity of CD127+ cells, or block downstream signaling, to study the effects on immune responses, such as T cell survival, differentiation, and memory formation.
• Phenotyping via flow cytometry: Beyond blocking experiments, A7R34 is also used to label and analyze CD127 expression on mouse leukocyte subsets by flow cytometry, often as part of multiparametric immune profiling in studies of normal and pathological immune function.

A7R34 has helped define the biological importance of CD127 in murine models by enabling both loss-of-function (blocking) and cell-tracking (phenotyping) approaches in a wide variety of immunological contexts.

The A7R34 antibody, which targets mouse IL-7Rα (CD127), is most commonly used in combination with antibodies or proteins that help define lymphocyte populations, analyze receptor signaling pathways, and study immune cell development in the literature.

Commonly used companion antibodies or proteins with A7R34 include:

• CD132 (Common γ chain): Forms the high-affinity receptor complex with CD127 and is important for IL-7 signaling, so antibodies against CD132 are often used alongside A7R34 to study receptor composition and function.
• TSLPR (Thymic Stromal Lymphopoietin Receptor): CD127 can also pair with TSLPR to form the receptor for TSLP; so, TSLPR-specific antibodies are used to differentiate responses to IL-7 versus TSLP.
• Markers for lymphocyte lineage and maturation:
  • CD4 and CD8: To analyze thymocyte and T cell subsets, antibodies against CD4 and CD8 are frequently included.
  • B cell markers (e.g., B220, CD19): B cell development is affected by IL-7Rα signaling, so B cell markers are common in multi-color panels.
  • NK cell markers (such as NK1.1): For distinguishing thymic NK cells expressing CD127.
  • γδ TCR: Used to identify γδ T cells that also express CD127.
• Activation/Memory markers:
  • CD44, CD62L, and others: Since CD127 expression is modulated during T cell activation and memory formation, these markers are frequently analyzed with A7R34.
• Isotype controls: Rat IgG2a isotype controls are recommended for setting proper baselines in immunoassays using A7R34 to ensure specificity.

Applications most often involve flow cytometry, so the above antibodies/proteins are chosen based on panel design for identifying and characterizing T cell, B cell, or progenitor subsets in mouse models.

In summary, A7R34 is most commonly used with antibodies targeting CD132, TSLPR, CD4, CD8, B220/CD19, NK1.1, γδ TCR, and various activation/memory markers, depending on the research focus. The choice is dictated by the immunological population o

Clone A7R34 is a well-characterized rat monoclonal antibody that specifically binds to mouse CD127 (Interleukin-7 Receptor alpha chain, IL-7Rα) and is widely used to block IL-7 binding and analyze CD127 biology in immunology research.

Key findings from scientific literature using citations of clone A7R34 can be summarized as follows:

• Specificity and Blocking Capability: A7R34 binds specifically to mouse IL-7Rα (CD127) and is frequently used in flow cytometry to detect CD127 on various lymphoid cells. It is notable for its ability to completely block the binding of clone S18006K (another anti-IL-7Rα antibody) but does not block SB/199. Importantly, it blocks IL-7 binding to CD127, thus inhibiting IL-7-mediated signaling.
• Functional Implications: Through blocking IL-7 binding, A7R34 has been instrumental for dissecting the biological roles of IL-7R signaling, including regulation of T and B cell development and homeostasis. CD127 is crucial in lymphocyte lineage development, and its absence leads to severe impairment of both B and T cell maturation.
• Expression Patterns: A7R34 has helped reveal that CD127 is highly expressed on naive and memory T cells, early B and T cell progenitors, and other lymphoid populations. CD127 expression is dynamically regulated—downregulated upon activation and re-expressed during memory T cell differentiation.
• Autophagy and T Cell Activation: Recent findings indicate that CD127 (IL-7Rα) is degraded by autophagy in activated CD4+ T cells. The use of A7R34 contributed to identifying IL-7Rα as an autophagy target, linking autophagic regulation to T cell activation and memory formation. Notably, IL-7Rα accumulates in autophagy-deficient T cells, a phenomenon that has clarified distinct pathways for receptor regulation and turnover.
• Other Applications: A7R34 is also used to study dendritic cell biology, where IL-7Rα signaling can modulate CD4+ T cell homeostatic proliferation, with implications for immune responses in lymphopenic settings.

In summary:

• A7R34 is a tool antibody that blocks IL-7 binding, enabling study of CD127 roles in lymphocyte biology and immune regulation.
• It has provided insights into the regulators of T and B cell development, memory T cell formation, and the interplay between autophagy and cytokine receptor signaling in immune cells.

If you require a more detailed breakdown of PubMed-cited studies with experimental outcomes, please clarify further.

The dosing regimens of clone A7R34 in mouse models primarily depend on the application, the experimental design, and the specific cell population targeted. Most available protocols and commercial datasheets recommend dosing based on cell numbers for flow cytometry, rather than per mouse, and emphasize titration for optimal results.

• For flow cytometry staining, the recommended dose is ≤ 1.0 µg per million cells in 100 µL volume, though users are advised to titrate for each application.
• An example from BD Biosciences indicates use at 0.5 µg/test, typically referring to a standard staining of approximately 1 million cells per sample.
• The concentration for storage and preparation is commonly 0.5 mg/mL, but the dose used for assays should be titrated each time to suit the experimental design.

Mouse model variability:

• The actual dosing regimen does not appear to widely differ across mouse strains (e.g., C57BL/6, BALB/c), as recommendations are based on the number of cells rather than specific model characteristics.
• There is no explicit evidence in these search results of different dosing regimens for different disease models (such as infection, cancer, or autoimmunity); protocols generally call for optimization per experimental setup.

Blocking/inhibition studies:

• A7R34 is also used functionally to block IL-7 binding, with dose adjustments sometimes required depending on whether the goal is to inhibit receptor function in vivo or to stain for flow cytometry. However, standard dosage guidance for in vivo receptor blockade in whole mice is not provided in the referenced datasheets.

Summary Table:

In conclusion, A7R34 dosing regimens are primarily standardized by cell number and volume, with recommendations to titrate according to specific experimental conditions. There is no evidence of major dosing differences between mouse strains or disease models, but functional vs. staining applications may require dose adjustments and optimization.